Krka, tovarna zdravil, d.d., Novo Mesto (KN8.F) rose 3.2% to 260.0 EUR on October 26, 2026, putting the shares just under their October 7 closing peak of 261.5 EUR. The balance of evidence now leans positive, a change from the neutral reading of October 16. Conviction is low. The daily trend agrees with the weekly uptrend, but the stock still lags both the S&P 500 and the healthcare sector.
Why it matters
No news item explains the move. The feed holds no company announcement, no sector story and no market backdrop for the session, so the jump has to be judged on the price action alone. Volume is running 37.9% above its 20-day average, which says the buying was real participation rather than a thin print. It is still an early-session quote, and a single session does not settle much.
Much of the year's gain is already in the price. The stock is up 30.0% year to date and 37.93% above its 52-week low of 188.5 EUR. It remains 13.33% below the 52-week high of 300.0 EUR. At roughly 7.9 billion EUR of market value, the shares are not priced as a recovery story. They are priced as a stock that has already done most of its work this year and is now testing the top of a recent range.
The 5-day attribution is clean. KN8.F gained 3.2% over five days, while the S&P 500 fell 0.4% and XLV, the healthcare sector fund, rose 1.5%. The market contributed nothing, and the sector explains about 1.5 points of the move. The remaining 1.7 points are the stock's own. Today ran the same way: the stock rose 3.2% while SPY fell 0.52% and XLV fell 1.11%. Over longer windows the picture is less flattering. Against the S&P 500 the stock is behind by 1.9% over 50 days, and against XLV by 8.4%. XLV gained 6.2% over the past month, against 1.6% for KN8.F.
There is no debate to report. No articles on KN8.F were available, and analyst coverage is absent from the data: no consensus, no price target, no spread. The argument therefore comes from the tape. The case for the shares is a clean trend, with price above both the 50-day and 200-day averages. The case against is that the sector has been rewarded far more than this stock. With no price target to measure against, valuation cannot be set against an analyst range.
What the evidence says
The long-term thesis is intact. Price is above its 40-week average and above the 10-week average, and the 200-day average at 248.04 EUR sits well beneath the shares. The stock is in a recovery phase inside a larger uptrend, still 13.33% under its 300.0 EUR high. It has not yet cleared the October peak. The RSI at 59.72 shows momentum building without being stretched.
For the next 2–6 weeks the balance of evidence leans positive, with low conviction: 1 of 4 supporting points. The October 16 report was neutral, also at low conviction, because the daily trend and the weekly trend were not pointing the same way (alignment: none). The shares have since closed that gap. The daily trend now runs with the weekly uptrend, and that is the one point carrying the reading. The change in stance comes from that alignment, not from news.
The strongest case against this reading is relative weakness. A 50-day lag of 1.9% against the S&P 500 and 8.4% against XLV means money has preferred the sector to this stock, and a move that goes against that pattern after one session can fade. The price also has not closed above 261.0 EUR, the level that would confirm buyers are in control. This does not outweigh the trend structure, which is intact. It is the reason conviction is low rather than higher.
Levels that matter
The structure holds above 256.86 EUR, the 50-day average. A close under it would be the first crack. The trend ends below 255.59 EUR, a swing zone just beneath, on a weekly close. Further down, 250.08 EUR and the 200-day average at 248.04 EUR are the next supports. The October 16 report set its weekly-close marker at 246.88 EUR, the 200-day average at that date. The marker is now tighter because the shares have moved up.
The breakout level is a daily close above 261.0 EUR on volume above its 20-day average. From there the first target is 269.17 EUR, a reward-to-risk of 1.7 to 1, and the second is 272.75 EUR at 2.4 to 1. The stop sits at 256.15 EUR, a quarter of an ATR under the 50-day average, so a breakout failing below that level would be wrong. The math does not reach the 3 to 1 that makes a breakout worth the risk. It would take a target beyond 275.0 EUR, the next round number, or a stop closer to the entry. The 300.0 EUR high is the far edge of the map.
What would change the picture
A weekly close below 255.59 EUR would end the positive reading, because it would break the swing zone that anchors the trend. The non-price fact most likely to do it is the November 12 earnings report. A guidance cut or a clear miss would give the sector's stronger performers a reason to keep the lead, and would turn the recent lag against XLV from a nuisance into the main story.
What to watch
- Earnings on November 12, 2026: the number that matters is the full-year guidance. A confirmed or raised outlook supports the move to the October peak. A cut would challenge it.
- The sector: XLV rose 1.5% over five days and 6.2% over the month. Whether the sector holds or fades will move KN8.F before any company news does. A close for the stock above 261.0 EUR on above-average volume is what would show it is catching up.
- Valuation versus consensus: there is no analyst consensus, price target or spread in the data, so the shares carry no external anchor. The 52-week range of 188.5 to 300.0 EUR is the only valuation frame available.